Article
Immunology
Yang Su, Ruoshan Qi, Lanying Li, Xu Wang, Sijin Li, Xuan Zhao, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi
Summary: The study aims to construct an immune-related gene prognostic risk index (IRGPRI) for pancreatic adenocarcinoma (PAAD) and investigate the immune and molecular features in IRGPRI-defined PAAD subgroups and the benefit of immune checkpoint inhibitors (ICIs) therapy. By analyzing gene expression data and survival data, 16 immune-related hub genes were identified and an IRGPRI was constructed and validated in different datasets. Further analysis revealed that low IRGPRI patients had better overall survival and more clinical treatment benefits, while high IRGPRI patients were more inclined towards cancer-related pathways. These findings provide important information for prognosis assessment and ICIs treatment in PAAD.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Geeta G. Sharma, Yasuyuki Okada, Daniel Von Hoff, Ajay Goel
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy often diagnosed at an advanced stage, with poor 5-year survival rates. Non-coding RNAs (ncRNAs) are emerging as potential biomarkers for PDAC, playing a central role in tumor biology and offering opportunities for improving diagnosis, prognosis, and prediction outcomes.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Cell Biology
Guihua Jin, Qingqing Ruan, Fugen Shangguan, Linhua Lan
Summary: The study identified RUNX2 and LAMC2 as promising targets for early diagnosis and therapy of pancreatic carcinoma, based on integrative analysis of multiple datasets.
Review
Biochemistry & Molecular Biology
Helen B. Binang, Chamini J. Perera, Minoti V. Apte
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a common and deadly type of pancreatic cancer, often diagnosed at an advanced stage due to lack of detection strategies for asymptomatic patients. Diabetes mellitus (DM) is a significant risk factor for PDAC, with unique features known as pancreatic cancer-related diabetes (PCRD), lacking specific biomarkers to differentiate it from type 2 DM.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Ailin Wei, Huiling Zhao, Xue Cong, Linyao Wang, Yiyang Chen, Juxiang Gou, Ziyi Hu, Xiuying Hu, Yali Tian, Ka Li, Yufeng Deng, Haojiang Zuo, Mei Rosemary Fu
Summary: This study investigated the association between oral mycobiota and pancreatic ductal adenocarcinoma (PDAC). The findings suggest that PDAC patients have increased fungal abundance and decreased fungal diversity compared to healthy controls. Certain fungal species, such as Aspergillus and Cladosporium, showed high classification powers in distinguishing PDAC patients from healthy controls. The findings highlight the potential of using oral mycobiota as a biomarker for early detection and prevention of PDAC.
Article
Endocrinology & Metabolism
Francisco J. Osuna-Prieto, Jose Rubio-Lopez, Xinyu Di, Wei Yang, Isabelle Kohler, Patrick C. N. Rensen, Jonatan R. Ruiz, Borja Martinez-Tellez
Summary: The study suggests that plasma levels of bile acids may be sex dependent and associated with cardiometabolic and inflammatory risk factors in young and relatively healthy adults.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Oncology
Julie Lecuelle, Anne Aarnink, Zoe Tharin, Caroline Truntzer, Francois Ghiringhelli
Summary: This study demonstrates that exome sequencing can be used to predict survival in patients with advanced pancreatic ductal adenocarcinoma undergoing FOLFIRINOX treatment, with genomic features playing a crucial role in prognosis prediction for these patients.
Review
Gastroenterology & Hepatology
Robert S. O'Neill, Alina Stoita
Summary: Pancreatic cancer is a major cause of cancer-related mortality globally and is associated with poor prognosis. Current biomarkers used in the diagnosis of PC lack sensitivity and specificity, but liquid biopsy and diagnostic panels are showing efficacy in the diagnosis of PC. Promising developments in the early detection of PC include the detection of microRNA in serum and circulating tumor cells.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Genetics & Heredity
Jiantao Mo, Zhiwei Cui, Qiqi Wang, Weifan Zhang, Jie Li, Shuai Wu, Weikun Qian, Cancan Zhou, Qingyong Ma, Zheng Wang, Zheng Wu
Summary: This study aimed to construct a prognostic model for pancreatic adenocarcinoma (PAAD) based on necroptosis-related long non-coding RNAs (NRLs). Through genomic analysis and statistical methods, it was found that NRLs played a vital role in the prognosis of PAAD. The established prognostic model can be used for diagnosis and guidance of personalized immunotherapy.
FRONTIERS IN GENETICS
(2022)
Article
Public, Environmental & Occupational Health
Miquel Porta, Magda Gasull, Jose Pumarega, Hannu Kiviranta, Panu Rantakokko, Ole Raaschou-Nielsen, Ingvar A. Bergdahl, Torkjel Manning Sandanger, Antoni Agudo, Charlotta Rylander, Therese Haugdahl Nost, Carolina Donat-Vargas, Dagfinn Aune, Alicia K. Heath, Lluis Cirera, Fernando Goni-Irigoyen, Juan Alguacil, Alex Gimenez-Robert, Anne Tjonneland, Malin Sund, Kim Overvad, Francesca Romana Mancini, Vinciane Rebours, Marie-Christine Boutron-Ruault, Rudolf Kaaks, Matthias B. Schulze, Antonia Trichopoulou, Domenico Palli, Sara Grioni, Rosario Tumino, Alessio Naccarati, Salvatore Panico, Roel Vermeulen, J. Ramon Quiros, Miguel Rodriguez-Barranco, Sandra M. Colorado-Yohar, Maria-Dolores Chirlaque, Eva Ardanaz, Nick Wareham, Tim Key, Mattias Johansson, Neil Murphy, Pietro Ferrari, Inge Huybrechts, Veronique Chajes, Carlos Alberto Gonzalez, Bas Bueno-de-Mesquita, Marc Gunter, Elisabete Weiderpass, Elio Riboli, Eric J. Duell, Verena Katzke, Paolo Vineis
Summary: In a prospective cohort study, certain POPs were found to be associated with pancreatic cancer risk, especially in participants with longer fasting time, normal weight, and non-smokers. However, most of the 22 POPs analyzed did not significantly increase the risk of pancreatic cancer.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
(2022)
Article
Hematology
Florian Moik, Gerald Prager, Johannes Thaler, Florian Posch, Sarah Wiedemann, Theresa Schramm, Cornelia Englisch, Nigel Mackman, Ingrid Pabinger, Cihan Ay
Summary: The occurrence of VTE in pancreatic cancer patients is associated with shorter overall survival and progression-free survival. Higher levels of D-dimer, extracellular vesicle-tissue factor activity, PAI-1, and sP-selectin are independently prognostic for increased mortality. Furthermore, D-dimer can predict response to palliative chemotherapy.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Miguel A. Ortega, Oscar Fraile-Martinez, Leonel Pekarek, Cielo Garcia-Montero, Miguel Angel Alvarez-Mon, Alejandro J. Castellanos, Natalio Garcia-Honduvilla, Julia Bujan, Melchor Alvarez-Mon, Miguel A. Saez, Luis G. Guijarro, Angel Asunsolo
Summary: Pancreatic cancer is a malignancy that is becoming more prevalent, especially in developed countries due to dietary patterns and sedentary lifestyles. It is expected to become the second leading cause of cancer-related deaths in the near future. The low survival rate is attributed to the lack of symptoms in the early stages, leading to metastasis in advanced stages. This study evaluates molecular biomarkers and finds a correlation between their high expression and low survival rate in pancreatic cancer patients.
Article
Biochemistry & Molecular Biology
Xiaohui Xu, Kritisha Bhandari, Chao Xu, Katherine Morris, Wei-Qun Ding
Summary: Pancreatic cancer is a major cause of cancer-related deaths, and early detection is crucial for improving survival rates. Recent studies suggest that miRNA signatures in plasma small EVs could be potential biomarkers for early detection of pancreatic cancer. However, inconsistent results have been reported due to the heterogeneity of plasma small EVs and isolation methods. In this study, a refined protocol for plasma small EV isolation was used, and miRNA signatures were analyzed in a pilot cohort of early-stage pancreatic cancer patients. The results showed that miR-18a and miR-106a levels were significantly elevated in the plasma small EVs of PDAC patients, indicating their potential as biomarkers for early detection.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Giulia Peduzzi, Livia Archibugi, Verena Katzke, Manuel Gentiluomo, Gabriele Capurso, Anna Caterina Milanetto, Maria Gazouli, Mara Goetz, Hermann Brenner, Roel C. H. Vermeulen, Renata Talar-Wojnarowska, Giuseppe Vanella, Francesca Tavano, Maurizio Lucchesi, Beatrice Mohelnikova-Duchonova, Xuechen Chen, Vytautas Kiudelis, Peter Hegyi, Martin Oliverius, Hannah Stocker, Caterina Stornello, Ludmila Vodickova, Pavel Soucek, John P. Neoptolemos, Sabrina Gloria Giulia Testoni, Luca Morelli, Rita T. Lawlor, Daniela Basso, Jakob R. Izbicki, Stefano Ermini, Juozas Kupcinskas, Raffaele Pezzilli, Ugo Boggi, Hanneke W. M. van Laarhoven, Andrea Szentesi, Balint Eross, Giovanni Capretti, Ben Schottker, Jurgita Skieceviciene, Mateus Nobrega Aoki, Casper H. J. van Eijck, Giulia Martina Cavestro, Federico Canzian, Daniele Campa
Summary: The study found that common polymorphisms in the estrogen and pregnenolone pathways were not identified to be associated with the risk of pancreatic ductal adenocarcinoma (PDAC). However, the association between NR5A2 gene variants and PDAC risk was validated.
SCIENTIFIC REPORTS
(2022)
Review
Biochemistry & Molecular Biology
Reiko Yamada, Junya Tsuboi, Yumi Murashima, Takamitsu Tanaka, Kenji Nose, Hayato Nakagawa
Summary: Pancreatic cancer is often diagnosed at late stages, making treatment difficult. Early diagnosis is crucial, but it can be challenging due to nonspecific symptoms. Recent studies suggest that selective screening and biomarkers can improve early detection. This review discusses advancements in imaging, biomarkers, biopsies, surveillance, and machine learning for identifying high-risk individuals. These new methods and techniques have the potential to improve overall survival in pancreatic cancer patients.